flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 πΈπͺ #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Semaglutide could be 'practice changing'
Pay in 4 interest-free payments of $6.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Oct 8 - Oct 13








:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)













![Terrible Creator Android 20 (Level 2) (BT2-093) [Judge Promotion Cards] 234](https://cdn.shopify.com/s/files/1/0266/9513/9533/files/aa31dd28-f51a-59ba-a197-03738d7ce633.jpg?v=1768246134)


